Published in Curr Opin Pharmacol on June 07, 2013
Lipoxin A4 Attenuates Obesity-Induced Adipose Inflammation and Associated Liver and Kidney Disease. Cell Metab (2015) 0.84
Anti-inflammatory and Antioxidative Activities of Safranal in the Reduction of Renal Dysfunction and Damage that Occur in Diabetic Nephropathy. Inflammation (2015) 0.77
Hydrogen Sulfide Mitigates Kidney Injury in High Fat Diet-Induced Obese Mice. Oxid Med Cell Longev (2016) 0.75
The ZDSD rat: a novel model of diabetic nephropathy. Am J Transl Res (2017) 0.75
Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature (2007) 11.59
CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest (2005) 10.44
Resolution of inflammation: the beginning programs the end. Nat Immunol (2005) 9.81
Adipokines in inflammation and metabolic disease. Nat Rev Immunol (2011) 8.92
Weight loss and lipolysis promote a dynamic immune response in murine adipose tissue. J Clin Invest (2010) 4.56
Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A (2010) 3.60
Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J (2009) 2.83
Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. Blood (2012) 2.37
Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? Am J Pathol (2010) 2.16
Functional heterogeneity of CD11c-positive adipose tissue macrophages in diet-induced obese mice. J Biol Chem (2010) 2.14
Human adipose tissue macrophages: m1 and m2 cell surface markers in subcutaneous and omental depots and after weight loss. J Clin Endocrinol Metab (2009) 2.14
Hematopoietic prostaglandin D2 synthase controls the onset and resolution of acute inflammation through PGD2 and 15-deoxyDelta12 14 PGJ2. Proc Natl Acad Sci U S A (2007) 2.10
The role of adipose tissue and lipotoxicity in the pathogenesis of type 2 diabetes. Curr Diab Rep (2010) 1.98
Adipose tissue macrophages in insulin-resistant subjects are associated with collagen VI and fibrosis and demonstrate alternative activation. Am J Physiol Endocrinol Metab (2010) 1.94
CKD in Hispanics: Baseline characteristics from the CRIC (Chronic Renal Insufficiency Cohort) and Hispanic-CRIC Studies. Am J Kidney Dis (2011) 1.88
MicroRNAs in resolution of acute inflammation: identification of novel resolvin D1-miRNA circuits. FASEB J (2010) 1.87
Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype. J Immunol (2011) 1.87
Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun (2003) 1.82
Specialized pro-resolving lipid mediators in the inflammatory response: An update. Biochim Biophys Acta (2010) 1.72
Resolvin D1 decreases adipose tissue macrophage accumulation and improves insulin sensitivity in obese-diabetic mice. FASEB J (2011) 1.72
Saturated-efferocytosis generates pro-resolving CD11b low macrophages: modulation by resolvins and glucocorticoids. Eur J Immunol (2010) 1.70
Annexin 1 mediates the rapid anti-inflammatory effects of neutrophil-derived microparticles. Blood (2008) 1.61
Defining macrophage phenotype and function in adipose tissue. Trends Immunol (2011) 1.57
Cutting edge: Humanized nano-proresolving medicines mimic inflammation-resolution and enhance wound healing. J Immunol (2011) 1.52
MGL1 promotes adipose tissue inflammation and insulin resistance by regulating 7/4hi monocytes in obesity. J Exp Med (2009) 1.46
Obesity-related chronic kidney disease is associated with spleen-derived IL-10. Nephrol Dial Transplant (2012) 1.40
Adipose tissue macrophages: phenotypic plasticity and diversity in lean and obese states. Curr Opin Clin Nutr Metab Care (2011) 1.37
Obesity, airway hyperresponsiveness, and inflammation. J Appl Physiol (1985) (2009) 1.34
Resolvin D1 and resolvin D2 govern local inflammatory tone in obese fat. J Immunol (2012) 1.31
Proresolution therapy for the treatment of delayed healing of diabetic wounds. Diabetes (2012) 1.27
Role of adipose tissue renin-angiotensin system in metabolic and inflammatory diseases associated with obesity. Kidney Int (2010) 1.24
Systemic inflammation and insulin sensitivity in obese IFN-γ knockout mice. Metabolism (2012) 1.22
Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes. Diabetologia (2012) 1.16
Obesity related kidney disease. Curr Diabetes Rev (2011) 1.14
Comparison of overall obesity and abdominal adiposity in predicting chronic kidney disease incidence among adults. J Ren Nutr (2009) 1.14
Angiotensin type 1 receptor modulates macrophage polarization and renal injury in obesity. Am J Physiol Renal Physiol (2011) 1.13
Synergistic induction of lipid catabolism and anti-inflammatory lipids in white fat of dietary obese mice in response to calorie restriction and n-3 fatty acids. Diabetologia (2011) 1.10
Elevated expressions of 15-lipoxygenase and lipoxin A4 in children with acute poststreptococcal glomerulonephritis. Am J Pathol (2008) 1.08
Microfluidic chambers for monitoring leukocyte trafficking and humanized nano-proresolving medicines interactions. Proc Natl Acad Sci U S A (2012) 1.08
Resolvins E1 and D1 inhibit interstitial fibrosis in the obstructed kidney via inhibition of local fibroblast proliferation. J Pathol (2012) 1.06
Lymphocytes in obesity-related adipose tissue inflammation. Diabetologia (2012) 1.04
Impaired local production of proresolving lipid mediators in obesity and 17-HDHA as a potential treatment for obesity-associated inflammation. Diabetes (2013) 1.02
Annexin 1 mimetic peptide protects against renal ischemia/reperfusion injury in rats. J Mol Med (Berl) (2010) 1.01
Lipoxin A4 attenuates adipose inflammation. FASEB J (2012) 1.00
Lipoxins attenuate renal fibrosis by inducing let-7c and suppressing TGFβR1. J Am Soc Nephrol (2013) 0.96
Lipoxin A₄ and benzo-lipoxin A₄ attenuate experimental renal fibrosis. FASEB J (2011) 0.96
Resolution of inflammation: therapeutic potential of pro-resolving lipids in type 2 diabetes mellitus and associated renal complications. Front Immunol (2012) 0.92
Resolution of adipose tissue inflammation. ScientificWorldJournal (2010) 0.90
Omega-3 fatty acid supplementation in advanced kidney disease. Semin Dial (2010) 0.88
A 12-week regimen of caloric restriction improves levels of adipokines and pro-inflammatory cytokines in Korean women with BMIs greater than 23 kg/m2. Inflamm Res (2009) 0.87
Autacoid 14S,21R-dihydroxy-docosahexaenoic acid counteracts diabetic impairment of macrophage prohealing functions. Am J Pathol (2011) 0.85
The endogenous pro-resolving mediators lipoxin A4 and resolvin E1 preserve organ function in allograft rejection. Prostaglandins Leukot Essent Fatty Acids (2010) 0.84
The effect of pioglitazone treatment on 15-epi-lipoxin A4 levels in patients with type 2 diabetes. Atherosclerosis (2012) 0.83
Role of mineralocorticoid receptor and renin-angiotensin-aldosterone system in adipocyte dysfunction and obesity. J Steroid Biochem Mol Biol (2013) 0.82
Differential dose effect of fish oil on inflammation and adipose tissue gene expression in chronic kidney disease patients. Nutrition (2013) 0.82
15-Deoxy-Δ(12,14)-prostaglandin J2 exerts pro- and anti-inflammatory effects in mesangial cells in a concentration-dependent manner. Inflamm Allergy Drug Targets (2012) 0.81
Molecular circuits of resolution in renal disease. ScientificWorldJournal (2010) 0.80
Low plasma adiponectin levels predict increased urinary albumin/creatinine ratio in type 2 diabetes patients. Int Urol Nephrol (2011) 0.80
The effect of n-3 polyunsaturated fatty acids on leukotriene B₄ and leukotriene B₅ production from stimulated neutrophil granulocytes in patients with chronic kidney disease. Prostaglandins Leukot Essent Fatty Acids (2011) 0.80
Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes. Am J Physiol Heart Circ Physiol (2012) 0.80
Resolution pathways in inflammation: the devil in the adipose tissues and in the details. Focus on "Diversity of lipid mediators in human adipose tissue depots". Am J Physiol Cell Physiol (2013) 0.79
Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab (2008) 6.22
Mouse models of diabetic nephropathy. J Am Soc Nephrol (2004) 3.95
Mouse models of diabetic nephropathy. J Am Soc Nephrol (2009) 3.74
Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int (2009) 3.19
A simplified method for HPLC determination of creatinine in mouse serum. Am J Physiol Renal Physiol (2004) 2.17
The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway. Kidney Int (2005) 2.02
Utility of endogenous creatinine clearance as a measure of renal function in mice. Kidney Int (2004) 2.00
AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function. J Clin Invest (2013) 1.84
A1C and survival in maintenance hemodialysis patients. Diabetes Care (2007) 1.75
Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. J Am Soc Nephrol (2010) 1.75
Selective role for superoxide in InsP3 receptor-mediated mitochondrial dysfunction and endothelial apoptosis. J Cell Biol (2005) 1.73
Multiple metabolic hits converge on CD36 as novel mediator of tubular epithelial apoptosis in diabetic nephropathy. PLoS Med (2005) 1.71
Ultrasound molecular imaging of tumor angiogenesis with an integrin targeted microbubble contrast agent. Invest Radiol (2011) 1.64
Induction of AMPK activity corrects early pathophysiological alterations in the subtotal nephrectomy model of chronic kidney disease. Am J Physiol Renal Physiol (2013) 1.63
Molecular profiling of diabetic mouse kidney reveals novel genes linked to glomerular disease. Diabetes (2004) 1.58
Reactive oxygen species production via NADPH oxidase mediates TGF-beta-induced cytoskeletal alterations in endothelial cells. Am J Physiol Renal Physiol (2005) 1.58
Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol (2012) 1.51
AMPK mediates the initiation of kidney disease induced by a high-fat diet. J Am Soc Nephrol (2011) 1.48
Pirfenidone is renoprotective in diabetic kidney disease. J Am Soc Nephrol (2009) 1.29
New pharmacological treatments for improving renal outcomes in diabetes. Nat Rev Nephrol (2010) 1.29
Assessment of 115 candidate genes for diabetic nephropathy by transmission/disequilibrium test. Diabetes (2005) 1.25
Role of Nox2 in diabetic kidney disease. Am J Physiol Renal Physiol (2013) 1.24
Role of Smad4 on TGF-beta-induced extracellular matrix stimulation in mesangial cells. Kidney Int (2003) 1.24
Overview: combating diabetic nephropathy. J Am Soc Nephrol (2003) 1.22
Decorin deficiency enhances progressive nephropathy in diabetic mice. Am J Pathol (2007) 1.22
Transcription factors in the pathogenesis of diabetic nephropathy. Expert Rev Mol Med (2009) 1.21
Role of upstream stimulatory factors in regulation of renal transforming growth factor-beta1. Diabetes (2005) 1.21
Regulation of transforming growth factor beta in diabetic nephropathy: implications for treatment. Semin Nephrol (2007) 1.20
The endoplasmic reticulum stress response and diabetic kidney disease. Am J Physiol Renal Physiol (2011) 1.16
Obesity related kidney disease. Curr Diabetes Rev (2011) 1.14
Sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Curr Opin Nephrol Hypertens (2010) 1.12
Mechanisms of kidney fibrosis and the role of antifibrotic therapies. Curr Opin Nephrol Hypertens (2009) 1.09
TRB3 is stimulated in diabetic kidneys, regulated by the ER stress marker CHOP, and is a suppressor of podocyte MCP-1. Am J Physiol Renal Physiol (2010) 1.08
Nitrative inactivation of thioredoxin-1 and its role in postischemic myocardial apoptosis. Circulation (2006) 1.07
Novel interactions between TGF-{beta}1 actions and the 12/15-lipoxygenase pathway in mesangial cells. J Am Soc Nephrol (2004) 1.06
Glycemic control in diabetic CKD patients: where do we stand? Am J Kidney Dis (2008) 1.05
The role of aldosteronism in causing obesity-related cardiovascular risk. Cardiol Clin (2010) 1.04
A role for the organic anion transporter OAT3 in renal creatinine secretion in mice. Am J Physiol Renal Physiol (2012) 1.02
Diabetic nephropathy: of mice and men. Adv Chronic Kidney Dis (2005) 1.02
Hyperglycemia is a major determinant of albumin permeability in diabetic microcirculation: the role of mu-calpain. Diabetes (2007) 1.02
TGF-beta-induced Ca(2+) influx involves the type III IP(3) receptor and regulates actin cytoskeleton. Am J Physiol Renal Physiol (2002) 1.01
Fisetin lowers methylglyoxal dependent protein glycation and limits the complications of diabetes. PLoS One (2011) 1.00
Burnt-out diabetes: impact of chronic kidney disease progression on the natural course of diabetes mellitus. J Ren Nutr (2009) 0.99
Transition of kidney tubule cells to a senescent phenotype in early experimental diabetes. Am J Physiol Cell Physiol (2010) 0.97
Loss of heparan N-sulfotransferase in diabetic liver: role of angiotensin II. Diabetes (2005) 0.94
Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy. Nephrol Dial Transplant (2010) 0.94
Klotho suppresses renal tubulo-interstitial fibrosis by controlling basic fibroblast growth factor-2 signalling. J Pathol (2014) 0.93
Stimulation of urinary TGF-beta and isoprostanes in response to hyperglycemia in humans. Clin J Am Soc Nephrol (2005) 0.93
Transforming growth factor-beta: a clinical target for the treatment of diabetic nephropathy. Curr Diab Rep (2004) 0.93
Isoform- and species-specific control of inositol 1,4,5-trisphosphate (IP3) receptors by reactive oxygen species. J Biol Chem (2014) 0.93
Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels. Am J Kidney Dis (2002) 0.92
Uncoupling of ER-mitochondrial calcium communication by transforming growth factor-beta. Am J Physiol Renal Physiol (2008) 0.90
Profiling of human mesangial cell subproteomes reveals a role for calmodulin in glucose uptake. Am J Physiol Renal Physiol (2007) 0.89
Beneficial Effects of AMP-Activated Protein Kinase Agonists in Kidney Ischemia-Reperfusion: Autophagy and Cellular Stress Markers. Nephron Exp Nephrol (2014) 0.89
Visualizing the mouse podocyte with multiphoton microscopy. Biochem Biophys Res Commun (2012) 0.88
Mannan-binding lectin in diabetic kidney disease: the impact of mouse genetics in a type 1 diabetes model. Exp Diabetes Res (2012) 0.88
Role of reactive oxygen species in hyperadrenergic hypertension: biochemical, physiological, and pharmacological evidence from targeted ablation of the chromogranin a (Chga) gene. Circ Cardiovasc Genet (2010) 0.88
Role of the USF1 transcription factor in diabetic kidney disease. Am J Physiol Renal Physiol (2011) 0.87
A sensitized screen of N-ethyl-N-nitrosourea-mutagenized mice identifies dominant mutants predisposed to diabetic nephropathy. J Am Soc Nephrol (2006) 0.87
Targeted renal therapies through microbubbles and ultrasound. Adv Drug Deliv Rev (2010) 0.87
Antifibrotic treatment and other new strategies for improving renal outcomes. Contrib Nephrol (2011) 0.86
Genomic strategies for diabetic nephropathy. J Am Soc Nephrol (2003) 0.84
Renal dysfunction in heart failure patients: what is the evidence? Heart Fail Rev (2007) 0.83
Effects of water restriction on gene expression in mouse renal medulla: identification of 3betaHSD4 as a collecting duct protein. Am J Physiol Renal Physiol (2006) 0.83
In vivo validation and 3D visualization of broadband ultrasound molecular imaging. Am J Nucl Med Mol Imaging (2013) 0.82
Autophagy and metabolic changes in obesity-related chronic kidney disease. Nephrol Dial Transplant (2013) 0.81
Obesity and kidney disease: differential effects of obesity on adipose tissue and kidney inflammation and fibrosis. Curr Opin Nephrol Hypertens (2015) 0.81
Renal handling of adipokines. Contrib Nephrol (2006) 0.80
Sugar, sex, and TGF-β in diabetic nephropathy. Semin Nephrol (2012) 0.80
The pathogenesis of fibrosis and renal disease in scleroderma: recent insights from glomerulosclerosis. Curr Rheumatol Rep (2004) 0.80
Novel aspects of transforming growth factor-Beta in diabetic kidney disease. Nephron (2002) 0.80
Adipokines protecting CKD. Nephrol Dial Transplant (2013) 0.77
TGF-beta inhibits Ang II-induced MAPK p44/42 signaling in vascular smooth muscle cells by Ang II type 1 receptor downregulation. J Vasc Res (2009) 0.77
Metabolomics in Diabetic Kidney Disease: Unraveling the Biochemistry of a Silent Killer. Am J Nephrol (2016) 0.77
Effects of high-fat diet and losartan on renal cortical blood flow using contrast ultrasound imaging. Am J Physiol Renal Physiol (2013) 0.76
Regulation of transforming growth factor-beta1 by insulin in prediabetic African Americans. Kidney Int (2010) 0.75